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Sir,
In their recent article, Zagouri et al (2013) show that high c-Met
expression is associated with a worse outcome in triple-negative (TN)
breast cancer, however the authors state that they ‘did not include
further markers such as basal cytokeratins and/or EGFR that may
identify a group of tumours that have a distinct adverse prognosis’.
This is a surprising omission, as data from several studies indicate that
TN tumours that express basal markers are distinct from those that do
not, and that these ‘Core Basal’ tumours have a worse outcome (Blows
et al, 2010). Whether c-Met contributes to this poorer prognosis
would therefore appear to be an important question to address.
In our own immunohistochemical (IHC) analysis, we identified
38 TN tumours from a cohort of 182 patients with invasive breast
cancer. We divided the TN group into ‘Core Basal’ (CB, n¼ 31)
and basal marker negative (referred to as ‘Unclassified’ (U), n¼ 7)
using a panel of antibodies to basal markers (Rakha et al, 2009;
Blows et al, 2010): CK5/6, CK14, CK17 and EGFR (with a cut-off
of 10% tumour reactivity to denote positivity). Positivity for any of the
basal markers placed the tumour in the CB group. The sections were
stained for c-Met (CVD13, Invitrogen) and the staining was scored
semi-quantitatively (0–3 for intensity and 0-4 for area of tumour
reactivity to give a sum score of 0–7). Both the cytoplasmic and
membranous scores were combined to give a total c-Met score
between 0 and 14. Analysing c-Met expression as a continuous
variable (Figure 1), CB tumours had a significantly higher median total
c-Met score of 8.4 (interquartile range (IQR)¼ 7.0-10.3) compared
with 6.0 (IQR¼ 5.7-7.0) for U tumours (Mann–Whitney test,
P¼ 0.008). By comparison, it is very possible that the high
c-Met expressing tumours in the study by Zagouri et al (2013) were
predominantly CB tumours, and this raises the possibility that patients
with CB tumours may derive more benefit from anti-c-Met therapy.
Knowledge of EGFR status may be of further clinical relevance.
There is growing evidence that c-Met and EGFR can crosstalk in a
variety of cancers (Lai et al, 2009). Amplification of the MET gene
has been described in Gefitinib/Erlotinib-resistant non-small-cell
lung cancer (NSCLC) cell lines, leading to persistent signalling via
the PI3K pathway (Bean et al, 2007; Engelman et al, 2007).
Moreover, treatment with a combination of a c-Met tyrosine kinase
inhibitor (PHA-665752) and Gefitinib resulted in reduced
PI3K/AKT signalling and growth inhibition in Gefitinib-resistant
NSCLC cells (Engelman et al, 2007). Similarly, in the presence
of Gefitinib, EGFR phosphorylation in the breast cancer
cell line SUM229 has been shown to be mediated by a
c-Met/c-Src-dependant pathway (Mueller et al, 2008). These
studies suggest that c-Met and EGFR have a compensatory
relationship, whereby inhibition of one receptor tyrosine kinase
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Figure 1. Box plot showing total c-Met scores for the Core Basal and
Unclassified groups of TN tumours. The whiskers represent the
minimum and maximum values (Mann–Whitney test, P¼ 0.008).
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(RTK) may result in the activation of the other, thus maintaining
downstream signalling (Lai et al, 2009). In our own analysis, we
found a positive correlation between c-Met and EGFR expression
(Spearman’s correlation coefficient¼ 0.290, Po0.001), indicating
that compensation may be possible in these tumours. While several
of the c-Met kinase inhibitors currently in clinical trials have
activity against multiple RTKs, it would seem appropriate to
consider EGFR expression (and other RTKs) when investigating
the clinical significance of c-Met; these data would be of clear
benefit in clinical trial design and patient selection.
In summary, the study by Zagouri et al (2013) provides further
evidence of the involvement of c-Met in breast cancer progression,
but the clinical impact of the study would have been enhanced by
addressing the expression of basal markers, including EGFR,
and this further supports the recognition of CB tumours as a
distinct subset of TN cancers.
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